{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:52:20Z","timestamp":1788274340427,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ygyno.2022.04.016","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:11:02Z","timestamp":1651165862000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium"],"prefix":"10.1016","volume":"166","author":[{"given":"C.G.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Moxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Queimado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cohoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Dockery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.04.016_bb0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crad.2006.06.015","article-title":"Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis","volume":"62","author":"Sohaib","year":"2007","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0010","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in recurrent cervical Cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical Cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0025","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"JCO."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0030","series-title":"FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression during or after Chemotherapy","author":"C. for D.E. and Research","year":"2019"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0035","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical Cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0040","series-title":"FDA Grants Accelerated Approval to Pembrolizumab for First Tissue\/Site Agnostic Indication","author":"C. for D.E. and Research","year":"2019"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0045","series-title":"FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma","author":"C. for D.E. and Research","year":"2021"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0050","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/jnci\/djaa041","article-title":"Moving forward in cervical Cancer: enhancing susceptibility to DNA repair inhibition and damage, an NCI clinical trials planning meeting report","volume":"112","author":"Harkenrider","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0055","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.32143","article-title":"Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas","volume":"145","author":"Yi","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Integrated Genomic Analyses of Ovarian Carcinoma","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0065","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0070","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0075","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3390\/cancers12092407","article-title":"Genetic susceptibility to endometrial Cancer: risk factors and clinical management","volume":"12","author":"D\u00f6rk","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.molmed.2017.10.007","article-title":"Characterization, detection, and treatment approaches for homologous recombination deficiency in Cancer","volume":"23","author":"O\u2019Kane","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0090","doi-asserted-by":"crossref","first-page":"84579","DOI":"10.18632\/oncotarget.19961","article-title":"Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials","volume":"8","author":"MacKay","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0095","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1158\/1078-0432.CCR-19-0848","article-title":"Germline BRCA-associated endometrial carcinoma is a distinct clinicopathologic entity","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100660","article-title":"Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer","volume":"45","author":"Zhou","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ygyno.2020.12.010","article-title":"Clinical significance of homologous recombination deficiency score testing in endometrial Cancer","volume":"160","author":"Siedel","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/1541-7786.MCR-13-0628","article-title":"Hypoxic stress facilitates acute activation and chronic downregulation of Fanconi Anemia proteins","volume":"12","author":"Scanlon","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clinical Trials."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0120","series-title":"The Statistical Analysis of Failure Time Data","first-page":"1","article-title":"The statistical analysis of failure time data","author":"Kalbfleisch","year":"2002"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/COC.0b013e31829a2974","article-title":"Advances in the management of recurrent endometrial cancer","volume":"38","author":"Bradford","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0135","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial Cancer: a gynecologic oncology group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0140","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0145","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","article-title":"Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0150","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","article-title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","volume":"29","author":"Mirza","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/GCO.0000000000000428","article-title":"Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer","volume":"30","author":"McCann","year":"2018","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11523-020-00780-4","article-title":"Phase I study of Rucaparib in combination with bevacizumab in ovarian Cancer patients: maximum tolerated dose and pharmacokinetic profile","volume":"16","author":"Lorusso","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0165","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-18-4222","article-title":"Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy","volume":"25","author":"Park","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0170","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.molmed.2007.07.003","article-title":"Chromatin remodeling and cancer, part I: covalent histone modifications","volume":"13","author":"Wang","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev-pathmechdis-012418-012917","article-title":"SWI\/SNF complex mutations in gynecologic cancers: molecular mechanisms and models","volume":"15","author":"Wang","year":"2020","journal-title":"Annual Rev. Pathology Mechanisms Disease"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0185","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2017.10.028","article-title":"Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma","volume":"68","author":"Hu","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11673-020-10073-0","article-title":"The costs of institutional racism and its ethical implications for healthcare","volume":"18","author":"Elias","year":"2021","journal-title":"Bioeth. Inq."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.socscimed.2013.09.006","article-title":"Systemic racism and U.S. health care","volume":"103","author":"Feagin","year":"2014","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2105\/AJPH.93.2.277","article-title":"The structuring of ethnic inequalities in health: economic position, racial discrimination, and racism","volume":"93","author":"Nazroo","year":"2003","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0205","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)32032-8","article-title":"Reckoning with histories of medical racism and violence in the USA","volume":"396","author":"Nuriddin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0210","series-title":"Public Health, Racism, and the Lasting Impact of Hospital Segregation - Emily A. Largent","year":"2018"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0215","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2015.05.014","article-title":"Minority participation in gynecologic oncology group (GOG) studies","volume":"138","author":"Scalici","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cct.2013.03.007","article-title":"A systematic review of the factors influencing African Americans\u2019 participation in cancer clinical trials","volume":"35","author":"Rivers","year":"2013","journal-title":"Contemporary Clin. Trials"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0225","series-title":"Cancer and Society: A Multidisciplinary Assessment and Strategies for Action","first-page":"59","article-title":"Clinical trials: not for the poor and the old","author":"Clancy","year":"2019"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0230","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14649365.2014.994670","article-title":"Neoliberal racism: the \u2018southern strategy\u2019 and the expanding geographies of white supremacy","volume":"16","author":"Inwood","year":"2015","journal-title":"Soc. Cult. Geogr."},{"key":"10.1016\/j.ygyno.2022.04.016_bb0235","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1215\/03616878-8641481","article-title":"Racism and the political economy of COVID-19: will we continue to resurrect the past?","volume":"45","author":"Bailey","year":"2020","journal-title":"J. Health Polit. Policy Law"},{"key":"10.1016\/j.ygyno.2022.04.016_bb0240","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2307\/2657939","article-title":"Race and social welfare policy: the social security act of 1935","volume":"112","author":"Davies","year":"1997","journal-title":"Political Sci. Quarterly."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:23Z","timestamp":1758772823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0090825822002578"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.04.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}